Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Rotterdam – page 34

796 clinical trials in Rotterdam, The Netherlands across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Rotterdam at a glance
796
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

796 trials in Rotterdam

Open in trial search

Glioblastoma

Not yet recruiting

Study of NMS-03305293 and Temozolomide for Adults with Recurrent Glioblastoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nms-03305293
  • Sponsor:Nerviano Medical Sciences S.r.l.

Iron deficiency+2

Not yet recruiting

Study on Iron Infusion with Ferric Carboxymaltose for Elderly Patients with Severe Aortic Stenosis and Iron Deficiency Undergoing TAVI

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Carboxymaltose
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Ischaemic stroke+1

Not yet recruiting

Study on Stopping Atorvastatin in Frail Patients Aged 70+ with Recent Ischemic Stroke or Transient Ischemic Attack

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Atorvastatin
  • Sponsor:Amsterdam UMC Stichting

Cholangiocarcinoma

Not yet recruiting

Study of Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Study on the Safety and Effectiveness of Filgotinib for Patients with Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Colorectal cancer+1

Not yet recruiting

Study on Irinotecan and mFOLFOX4-Bevacizumab for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:Seqirus UK Limited

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Rotterdam

What the registry says about research in the country

01 Neurology and Mental Health

Innovative research focusing on frontotemporal dementia treatments and management of migraine in relation to obesity. Studies include evaluation of new therapeutic compounds and their effects on neurological conditions.

  • Dementia Treatment Studies
  • Migraine Management Research
  • Neurological Disease Interventions

Research aims to improve patient outcomes through targeted therapeutic approaches and innovative treatment methods.

02 Oncology and Cancer Research

Comprehensive studies targeting various forms of cancer, including advanced gastric cancer and bladder cancer. Research includes innovative imaging techniques and combination therapy approaches.

  • Gastric Cancer Treatment
  • Cancer Immunotherapy
  • Diagnostic Imaging Studies

Focus on developing more effective treatment strategies and improving diagnostic capabilities.

03 Metabolic and Endocrine Disorders

Clinical trials addressing obesity and related metabolic conditions, including innovative approaches to weight management and metabolic disease treatment. Studies evaluate new therapeutic options for thyroid disorders.

  • Weight Management Therapies
  • Thyroid Disease Treatment
  • Metabolic Disease Research

Research focuses on developing effective treatments for complex metabolic conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.